CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-23 | Wang Lai Global Head of R&D | Sale | −1,028 | $260.00 | $267K | 0 |
| 2025-06-23 | Wu Xiaobin President and COO | Sale | −1,363 | $260.00 | $354K | 0 |
| 2025-06-23 | OYLER JOHN Chief Executive Officer | Sale | −3,074 | $261.57 | $804K | 100 |
| 2025-06-23 | OYLER JOHN Chief Executive Officer | Sale | −100 | $262.90 | $26K | 0 |
| 2025-06-17 | Wang Lai Global Head of R&D | Sale | −470 | $251.37 | $118K | 0 |
| 2025-06-17 | Wu Xiaobin President and COO | Sale | −630 | $250.87 | $158K | 0 |
| 2025-06-17 | OYLER JOHN Chief Executive Officer | Sale | −1,460 | $256.49 | $374K | 0 |
| 2025-06-16 | Lee Chan Henry SVP, General Counsel | Sale | −422 | $266.50 | $112K | 0 |
| 2025-06-16 | Wang Lai Global Head of R&D | Sale | −1,177 | $266.40 | $314K | 470 |
| 2025-06-16 | Wu Xiaobin President and COO | Sale | −1,443 | $265.47 | $383K | 730 |
| 2025-06-16 | Wu Xiaobin President and COO | Sale | −100 | $266.22 | $27K | 630 |
| 2025-06-16 | OYLER JOHN Chief Executive Officer | Sale | −3,680 | $266.05 | $979K | 1,460 |
| 2025-06-11 | Ball Titus B. Principal Accounting Officer | Sale | −134 | $258.36 | $35K | 0 |
| 2025-06-10 | Ball Titus B. Principal Accounting Officer | Grant or award | +29,601 | 73,983 | ||
| 2025-06-10 | Lee Chan Henry SVP, General Counsel | Grant or award | +46,878 | 283,920 | ||
| 2025-06-10 | Lee Chan Henry SVP, General Counsel | Grant or award · Share Option (Right to Buy) | +88,244 | 88,244 | ||
| 2025-06-10 | Rosenberg Aaron Chief Financial Officer | Grant or award | +63,674 | 230,802 | ||
| 2025-06-10 | Rosenberg Aaron Chief Financial Officer | Grant or award · Share Option (Right to Buy) | +119,873 | 119,873 | ||
| 2025-06-10 | Wang Lai Global Head of R&D | Grant or award | +86,359 | 1,058,304 | ||
| 2025-06-10 | Wang Lai Global Head of R&D | Grant or award · Share Option (Right to Buy) | +162,565 | 162,565 |
Page 23 of 71 · 1,406 trades